Biopharmaceutical company GSK plc (LSE/: GSK ) (NYSE: GSK) announced on Wednesday that it has awarded USD2m in grant funding to 15 public health organisations through its COiMMUNITY Initiative, supporting efforts to improve adult immunization education, outreach and access.
Notable recipients include the American Heart Association, the Sepsis Alliance and the National Council on Aging, each addressing immunisation gaps in unique ways.
In 2025, GSK will commit an additional USD2m to further enhance vaccine awareness and accessibility.
Since launching in 2023, the COiMMUNITY Initiative has provided USD3m in funding to nonprofits nationwide, reinforcing GSK's commitment to overcoming barriers to adult immunization in the US.
Dx&Vx accelerates universal COVID-19 vaccine development
Moderna withdraws application for flu-COVID combination vaccine pending additional efficacy data
CTP delivers 18,000 sqm Serbian facility for SCHOTT Pharma to support global expansion
LakeShore Biopharma launches novel packaging solution for YSJA rabies vaccine (Vero cell)
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Orexo reports positive results for powder-based intranasal vaccine using AmorphOX technology
GC Biopharma's BARYTHRAX receives Korean regulatory approval
GSK grants USD2m to boost adult vaccination efforts
Valneva and LimmaTech begin Phase 2 infant trial for Shigella vaccine candidate S4V2
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100
Alzinova AB reports positive final Phase 1b results for ALZ-101 in Alzheimer's
Primrose Bio launches Prima RNApols ExTend RNA polymerase for long-template mRNA manufacturing
Merck's CAPVAXIVE approved by EC for pneumococcal disease prevention